Shareholder of Arcutis (NASDAQ: ARQT) to sell 1,320 vested shares

Rhea-AI Filing Summary

A shareholder of Arcutis Biotherapeutics plans to sell 1,320 common shares under Rule 144. The shares have an aggregate market value of $33,657.89, with Arcutis having 122,492,192 shares outstanding. The sale, through Merrill Lynch on NASDAQ, is expected around February 2, 2026.

The seller acquired the 1,320 shares on February 1, 2026 via restricted stock vesting from Arcutis Biotherapeutics, with payment on the same date. Over the prior three months, the same person sold 88 common shares on November 3, 2025 for gross proceeds of $2,155.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	1320	33657.89	122492192	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			1320	02/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Latha Vairavan 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	11/03/2025	88	2155

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ARQT Form 144 filing disclose about upcoming share sales?

The filing discloses a planned sale of 1,320 ARQT common shares under Rule 144. These shares, valued at $33,657.89, are expected to be sold on NASDAQ around February 2, 2026 through Merrill Lynch as broker.

How were the 1,320 Arcutis Biotherapeutics (ARQT) shares acquired?

The 1,320 ARQT common shares were acquired on February 1, 2026 through restricted stock vesting from Arcutis Biotherapeutics. The amount of securities acquired was 1,320 shares, with the date of payment also listed as February 1, 2026.

What prior ARQT share sales are reported in this Form 144 notice?

The notice reports that Latha Vairavan sold 88 ARQT common shares on November 3, 2025. Those shares generated $2,155 in gross proceeds. This history covers all securities of the issuer sold by this person during the past three months.

What is the size of Arcutis Biotherapeutics (ARQT) relative to the planned Rule 144 sale?

Arcutis Biotherapeutics has 122,492,192 common shares outstanding as referenced in the notice. The planned Rule 144 sale of 1,320 shares represents a very small portion of that total share count in this specific disclosure.

Which broker and exchange are involved in the ARQT Rule 144 share sale?

The planned sale of ARQT common shares will be executed through Merrill Lynch, listed at 8890 Lyra Drive, Columbus, Ohio. The securities are expected to be sold on the NASDAQ stock market, according to the Rule 144 notice details.

What representation does the ARQT selling shareholder make in this Form 144?

The selling shareholder represents that they do not know any material adverse information about Arcutis Biotherapeutics’ current or prospective operations that has not been publicly disclosed. This representation is made by signing the notice, as required under Rule 144.